UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-01, Vol.15 (2), p.723-730

2009

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Blood cancer journal (New York), 2021-05, Vol.11 (5), p.89-5, Article 89

2021

Link zum Volltext

Verfügbarkeit prüfen

Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant

Journal of the American Society of Nephrology, 2024-03, Vol.35 (3), p.347

2024

Link zum Volltext

Verfügbarkeit prüfen

Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

CPT: pharmacometrics and systems pharmacology, 2023-12, Vol.12 (12), p.1846-1858

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Blood, 2019-07, Vol.134 (2), p.123-133

2019

Link zum Volltext

Verfügbarkeit prüfen

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone

British journal of clinical pharmacology, 2022-05, Vol.88 (5), p.2052-2064

2022

Link zum Volltext

Verfügbarkeit prüfen

Preclinical profile of cabazitaxel

Drug design, development and therapy, 2014-01, Vol.8 (default), p.1851-1867

2014

Link zum Volltext

Verfügbarkeit prüfen

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

CPT: pharmacometrics and systems pharmacology, 2021-08, Vol.10 (8), p.928-940

2021

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2013-03, Vol.71 (3), p.681-692

2013

Link zum Volltext

Verfügbarkeit prüfen

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

CPT: pharmacometrics and systems pharmacology, 2022-06, Vol.11 (6), p.766-777

2022

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors

Clinical cancer research, 2013-06, Vol.19 (11), p.2973-2983

2013

Link zum Volltext

Verfügbarkeit prüfen

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

Leukemia, 2021-02, Vol.35 (2), p.562-572

2021

Link zum Volltext

Verfügbarkeit prüfen

Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein

Cancer chemotherapy and pharmacology, 2018-06, Vol.81 (6), p.1095-1103

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors

Anti-cancer drugs, 2015-03, Vol.26 (3), p.350-358

2015

Link zum Volltext

Verfügbarkeit prüfen

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

CPT: pharmacometrics and systems pharmacology, 2020-11, Vol.9 (11), p.649-658

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

BMC cancer, 2013-10, Vol.13 (1), p.460-460, Article 460

2013

Link zum Volltext

Verfügbarkeit prüfen

An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2014-06, Vol.73 (6), p.1241-1252

2014

Link zum Volltext

Verfügbarkeit prüfen

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and rats

British journal of pharmacology, 2003-04, Vol.138 (7), p.1367-1375

2003

Link zum Volltext

Verfügbarkeit prüfen

Abstract 749: A Phase I, open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.749-749

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1372: Model based approach to evaluate Isatuximab (Isa) monthly dosing regimen in relapsed/refractory multiple myeloma (RRMM)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1372-1372

2021

Link zum Volltext

Verfügbarkeit prüfen

Model Based Approach to Evaluate Isatuximab Monthly Dosing Regimen in Relapsed/Refractory Multiple Myeloma Patients

Blood, 2020-11, Vol.136 (Supplement 1), p.44-44

2020

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Blood, 2022-11, Vol.140 (Supplement 1), p.4412-4414

2022

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8025-8025

2022

Link zum Volltext

Verfügbarkeit prüfen

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.2744-2744

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(35)
Buchkapitel
(1)

Sprache

Englisch
(36)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Humans
(18)
Female
(12)
Pharmacology & Pharmacy
(12)
Male
(10)
Middle Aged
(10)
Oncology
(10)
Aged
(9)
Adult
(8)
Neoplasms - Drug Therapy
(8)
Multiple Myeloma - Drug Therapy
(7)
Tumors
(7)
Biological And Medical Sciences
(6)
Cabazitaxel
(6)
Medical Sciences
(6)
Pharmacokinetics
(6)
Aged, 80 And Over
(5)
Antineoplastic Agents - Pharmacokinetics
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1‑{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3‑b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844)

Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant

Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone

Preclinical profile of cabazitaxel

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein

A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and rats

Abstract 749: A Phase I, open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors

Abstract 1372: Model based approach to evaluate Isatuximab (Isa) monthly dosing regimen in relapsed/refractory multiple myeloma (RRMM)

Model Based Approach to Evaluate Isatuximab Monthly Dosing Regimen in Relapsed/Refractory Multiple Myeloma Patients

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

Suchergebnisse filtern